Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells.
Peter H GoffLaura RiolobosBonnie J LaFleurMatthew B SprakerY David SeoKimberly S SmytheJean S CampbellRobert H PierceYuzheng ZhangQianchuan HeEdward Y KimStephanie K SchaubGabrielle M KaneJose G MantillaEleanor Y ChenRobert W RicciottiMatthew J ThompsonLee D CranmerMichael J WagnerElizabeth Trice LoggersRobin L JonesErin MurphyWendy M BlumenscheinTerrill K McClanahanJon EarlsKevin C FlanaganNatalie A LaFranzoTeresa S KimSeth M PollackPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Standard neoadjuvant therapy induces both immunostimulatory and immunosuppressive effects within a complex sarcoma microenvironment dominated by myeloid and B cells. This work informs ongoing efforts to incorporate immune checkpoint inhibitors and novel immunotherapies into the neoadjuvant setting for STSs.